Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China

ObjectiveThe ASTRUM-005 trial demonstrated that adding serplulimab to chemotherapy significantly prolonged the survival of patients with extensive-stage small cell lung cancer (SCLC), but also increased the risk of adverse events. Given the high cost of serplulimab compared to chemotherapy, this stu...

Full description

Bibliographic Details
Main Authors: Guiyuan Xiang, Tingting Jiang, Lanlan Gan, Yuanlin Wu, Ni Zhang, Haiyan Xing, Hui Su, Yanping Li, Dan Peng, Rui Ni, Yao Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
cost-effectiveness
serplulimab
chemotherapy
extensive-stage small cell lung cancer
first-line treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1223020/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1223020/full

Similar Items